Isabel Weinhauser
Overview
Explore the profile of Isabel Weinhauser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Salustiano-Bandeira M, Moreira-Aguiar A, Pereira-Martins D, Coelho-Silva J, Weinhauser I, Franca-Neto P, et al.
Blood Cancer J
. 2024 Jun;
14(1):102.
PMID: 38914584
No abstract available.
2.
Rojas C, Pereira-Martins D, Bellido More C, Sternadt D, Weinhauser I, Hilberink J, et al.
Br J Haematol
. 2024 Apr;
204(6):2287-2300.
PMID: 38651345
Despite advancements in utilizing genetic markers to enhance acute myeloid leukaemia (AML) outcome prediction, significant disease heterogeneity persists, hindering clinical management. To refine survival predictions, we assessed the transcriptome of...
3.
Pereira-Martins D, Weinhauser I, Coelho-Silva J, Ammatuna E, Huls G, Schuringa J, et al.
Lancet Haematol
. 2024 Feb;
11(2):e98-e99.
PMID: 38302230
No abstract available.
4.
Weinhauser I, Pereira-Martins D, Hilberink J, Brouwers-Vos A, Rego E, Huls G, et al.
Haematologica
. 2023 Aug;
109(2):639-645.
PMID: 37646656
No abstract available.
5.
Lima A, Bezerra M, Moreira-Aguiar A, Weinhauser I, Santos B, Falcao R, et al.
Hematol Transfus Cell Ther
. 2023 Jul;
46(3):250-255.
PMID: 37393163
Introduction: The aberrant expression of the inhibitor of DNA binding (ID1) gene has been frequently associated with the leukemogenesis and prognostication acute myeloid leukemia (AML), although its clinical importance has...
6.
Weinhauser I, Pereira-Martins D, Almeida L, Hilberink J, Silveira D, Quek L, et al.
Sci Adv
. 2023 Apr;
9(15):eadf8522.
PMID: 37058562
It is increasingly becoming clear that cancers are a symbiosis of diverse cell types and tumor clones. Combined single-cell RNA sequencing, flow cytometry, and immunohistochemistry studies of the innate immune...
7.
Rojas C, Costa-Neto A, Pereira-Martins D, Le D, Sternadt D, Weinhauser I, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612292
Several laboratory and clinical variables have been reported to be associated with the outcome of intensive chemotherapy for acute myeloid leukemia (AML), but only a few have been tested in...
8.
Lima K, Pereira-Martins D, de Miranda L, Coelho-Silva J, da Silva Leandro G, Weinhauser I, et al.
Blood Cancer J
. 2022 Nov;
12(11):151.
PMID: 36347832
The treatment of acute leukemia is challenging because of the genetic heterogeneity between and within patients. Leukemic stem cells (LSCs) are relatively drug-resistant and frequently relapse. Their plasticity and capacity...
9.
Pereira-Martins D, Coelho-Silva J, Weinhauser I, Franca-Neto P, Silveira D, Ortiz C, et al.
Br J Haematol
. 2022 Oct;
200(2):170-174.
PMID: 36263593
Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients...
10.
Cunningham A, Erdem A, Alshamleh I, Geugien M, Pruis M, Pereira-Martins D, et al.
Blood
. 2022 Aug;
140(19):2037-2052.
PMID: 35984907
Targeting altered tumor cell metabolism might provide an attractive opportunity for patients with acute myeloid leukemia (AML). An amino acid dropout screen on primary leukemic stem cells and progenitor populations...